Cross-topic event
NEJM publishes Phase 3 retatrutide obesity results, with 25% weight loss at the top dose over 80 weeks (Metabolism)
Oct 3, 20262 reports
Oct 3, 2026
Sciencedesk view
NEJM publishes Phase 3 retatrutide obesity results, with 25% weight loss at the top dose over 80 weeks (Metabolism)
ScienceAlert reported on Oct 3 on TRIUMPH-1, a randomized double-blind trial led by Ania Jastreboff and funded by Eli Lilly. It assigned 2,339 adults with obesi…
READ THE DAY'S DIGEST →
Sports/Healthdesk view
NEJM: Weekly retatrutide produced up to 25.0% weight loss at 80 weeks on the treatment-regimen estimand in adults with obesity and without diabetes; the drug is not approved (Public health)
ScienceAlert reported on Oct 3, 2026, on TRIUMPH-1, led by Ania Jastreboff at Yale. The randomized double-blind phase 3 trial assigned 2,339 adults with obesity…
READ THE DAY'S DIGEST →